Selank and Semax: what the research shows

On peptide forums, Selank and Semax often appear in the same thread. Selank is described as anxiolytic; Semax as a focus enhancer. Combining them is a pattern some users report, typically framing Semax as a way to counteract any sedation they associate with Selank. This article explains what the published research says about each compound individually and why the rationale for combining them is, at present, built on preclinical and limited clinical evidence rather than controlled human data.

If you are managing generalised anxiety disorder (GAD) or another diagnosed condition, the conversation about any treatment belongs with a clinician. GAD is a recognised medical condition with established, evidence-backed therapies. Peptides discussed here are not approved medicines in the EU, UK, or US. For a broader look at grey-market peptide risks, see our guide to peptide grey-market risks.

What Selank is

Selank (TBEVA-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide developed at the Institute of Molecular Genetics in Moscow. It is a modified analogue of tuftsin, a tetrapeptide (Thr-Lys-Pro-Arg) that the spleen cleaves from immunoglobulin G and that has well-characterised immunomodulatory activity^[5]. Selank extends the tuftsin core with a Gly-Pro sequence that slows enzymatic breakdown, prolonging the peptide's activity. It was registered in Russia as a prescription anxiolytic nasal spray for GAD and neurasthenic conditions.

The best-characterised human study of Selank is a randomised trial by Zozulia and colleagues (2008) that enrolled 62 patients with GAD or neurasthenia and compared Selank with medazepam, a benzodiazepine anxiolytic^[1]. The trial found that anxiolytic effects of both drugs were similar on Hamilton and Zung scale measures, but Selank also produced antiasthenic and mild psychostimulant effects that medazepam did not. An important mechanistic finding was that patients with GAD showed lower-than-normal activity of enkephalin-degrading enzymes, and Selank treatment raised enkephalin activity. Enkephalins are endogenous opioid peptides involved in mood and stress regulation.

A 2014 comparison by Medvedev and colleagues matched Selank against phenazepam (a potent benzodiazepine used in Russian practice) and reported that Selank showed pronounced anxiolytic and mild nootropic effects, with benefits persisting for about a week after the final dose^[2]. The authors noted Selank's tolerability was better than phenazepam, with no dependence signal over the study period.

What this evidence base does not include: Western-standard multi-centre randomised trials conducted to FDA or EMA standards. The Russian-registered clinical work is real published research, but it is smaller and more concentrated in a single national setting than the body of evidence regulators in the EU or US require for marketing authorisation. For a related example of a grey-market peptide with a similar evidence profile, see our article on Semax grey-market risks.

What Semax is

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide derived from a fragment of adrenocorticotropic hormone (ACTH 4-7) extended with a Pro-Gly-Pro sequence. Like Selank, it was developed in Russia and is registered there as a prescription intranasal medicine, used primarily in ischemic stroke recovery and related cognitive rehabilitation contexts^[3].

The nootropic properties attributed to Semax in community discussions centre on its effects on brain-derived neurotrophic factor (BDNF). In a 2006 study, Dolotov and colleagues demonstrated that intranasal Semax at 50 to 250 mcg/kg produced a rapid and specific increase in BDNF protein levels in the rat basal forebrain within three hours of administration^[3]. The basal forebrain is a region involved in attention and memory. The study also characterised specific binding sites for Semax in basal forebrain membranes, with a dissociation constant of 2.4 nM, suggesting a direct receptor-mediated mechanism rather than a non-specific effect.

A separate 2005 study by Eremin and colleagues found that Semax raised striatal serotonin metabolite levels and amplified the dopaminergic response to stimulants in rodents^[4]. The authors described a positive modulatory effect on the striatal serotonergic system. This pattern, modulating both dopaminergic and serotoninergic tone, is consistent with the cognitive and mood-adjacent effects Semax users report, but translating rodent neurochemistry to human experience requires caution.

The rationale for combining them

Forum communities describe the Selank and Semax combination as targeting two distinct but complementary problems: Selank addressing anxiety, Semax addressing cognitive drive and focus. The theoretical logic is that anxiety and cognitive performance occupy separate but interacting biological domains, and that a compound acting on enkephalin and GABAergic pathways (Selank) could pair with one acting on BDNF and catecholamine tone (Semax) without obvious pharmacological antagonism.

That rationale is plausible in a general mechanistic sense. But plausible is not the same as tested. No published study, in humans or animals, has examined Selank and Semax administered together. There is no pharmacokinetic data on whether the intranasal peptides compete for the same mucosal uptake pathways when dosed simultaneously. There is no safety data characterising adverse effects from the combination. The combination is entirely a community extrapolation from individual compound profiles.

What we do not yet know

The evidence gaps are significant and worth naming directly. First, no Western-standard human RCT exists for either peptide. The Russian clinical literature is real, but it is not the kind of evidence base on which the FDA, EMA, or MHRA base marketing authorisation decisions. Second, the BDNF-elevating effect of Semax has been shown in rodent models; whether intranasal administration produces the same result in the human basal forebrain at the doses circulating in community forums is not established. Third, Selank's mechanism of action beyond enkephalin modulation is not fully characterised. Fourth, and most directly relevant to combining them: no pharmacokinetic or pharmacodynamic interaction data exist for the pair.

Regulatory status

Neither Selank nor Semax holds a marketing authorisation from the EMA, the MHRA, or any national medicines agency in the EU, EEA, or UK. In the US, both are classified as unapproved drugs. They are available in the grey market as research vials or repackaged Russian-format nasal sprays; that supply chain is not subject to the import controls, pharmacovigilance, or manufacturing oversight of any Western regulator. Importantly, the FDA Pharmacy Compounding Advisory Committee is scheduled in 2026 to review Semax, among other peptides, for placement on the 503A bulk substances list.

If you are considering either peptide

The published research on Selank and Semax, modest as it is, was conducted in supervised clinical or controlled laboratory settings. Self-administering unregulated peptides for a diagnosed condition like GAD bypasses the clinical oversight those studies included. If you are experiencing anxiety, established and licensed treatment options exist, including cognitive behavioural therapy, SSRIs, and short-term benzodiazepine use under supervision. Those options have the evidence base and the regulatory oversight that Selank and Semax currently lack. Please discuss any treatment decision with a clinician who knows your medical history.

**Medical disclaimer:** This article is for educational and journalistic purposes only and does not constitute medical advice. Selank and Semax are not approved medicines in the EU, UK, or US. Decisions about any treatment for generalised anxiety disorder or other medical conditions belong with a qualified healthcare professional. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.